UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Annals of oncology, 2019-03, Vol.30 (3), p.397-404

2019

Volltextzugriff (PDF)

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Annals of oncology, 2017-07, Vol.28 (7), p.1605-1611

2017

Volltextzugriff (PDF)

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Annals of oncology, 2021-09, Vol.32 (9), p.1148-1156

2021

Volltextzugriff (PDF)

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

Annals of oncology, 2019-08, Vol.30 (8), p.1381-1392

2019

Volltextzugriff (PDF)

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies

Annals of oncology, 2017-11, Vol.28 (11), p.2860-2865

2017

Volltextzugriff (PDF)

A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma

British journal of cancer, 2023-04, Vol.128 (6), p.1040-1051

2023

Volltextzugriff (PDF)

Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer

Breast (Edinburgh), 2020-12, Vol.54, p.303-310

2020

Volltextzugriff (PDF)

Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program

Oncogene, 2023-06, Vol.42 (23), p.1951-1956

2023

Volltextzugriff (PDF)

Immunothérapie et cancer du sein

Oncologie (Paris, France), 2016-09, Vol.18 (9-10), p.551-558

2016

Volltextzugriff (PDF)

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial

Annals of oncology, 2017-03, Vol.28 (3), p.590-596

2017

Volltextzugriff (PDF)

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer

British journal of cancer, 2024-09, Vol.131 (4), p.702-708

2024

Volltextzugriff (PDF)

Congrès Targeted Anticancer Therapies — TAT 2014

Oncologie (Paris, France), 2014, Vol.16 (7-8), p.367-378

2014

Volltextzugriff (PDF)

IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

Annals of oncology, 2024-07, Vol.35 (7), p.630-642

2024

Volltextzugriff (PDF)

Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program

Oncogene, 2023-04, Vol.42 (17), p.1417-1417

2023

Volltextzugriff (PDF)

A Therapeutic Challenge: Chemo-refractory Non-metastatic Inflammatory Breast Cancers

Clinical oncology (Royal College of Radiologists (Great Britain)), 2022-03, Vol.34 (3), p.e140-e140

2022

Volltextzugriff (PDF)

P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator’s choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy

Breast (Edinburgh), 2023-04, Vol.68, p.S23-S23

2023

Volltextzugriff (PDF)

Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets

European journal of cancer (1990), 2019-11, Vol.121, p.202-209

2019

Volltextzugriff (PDF)

Concurrent radiation therapy and dual HER2 blockade in breast cancer: Assessment of toxicity

Cancer radiothérapie, 2021-07, Vol.25 (5), p.424-431

2021

Volltextzugriff (PDF)

Association du double blocage de HER2 et radiothérapie dans la prise en charge du cancer du sein exprimant HER2

Cancer radiothérapie, 2021-07, Vol.25 (5), p.424-431

2021

Volltextzugriff (PDF)

1810 Neoadjuvant chemotherapy modifies the immune status of tumor-draining lymph nodes of breast cancer patients: Implications for immunotherapy

European journal of cancer (1990), 2015-09, Vol.51, p.S268-S268

2015

Volltextzugriff (PDF)

Immune-checkpoint myocarditis phenotype when using systematic troponin surveillance in cancer patients

European heart journal, 2024-10, Vol.45 (Supplement_1)

2024

Volltextzugriff (PDF)

The safety of standardized management of suspected cardiovascular immune-related events in patients treated by immunecheckpoints inhibitors

European heart journal, 2024-10, Vol.45 (Supplement_1)

2024

Volltextzugriff (PDF)

PO-1229 Radiotherapy-based management of non-metastatic Inflammatory breast cancers: a retrospective study

Radiotherapy and oncology, 2022-05, Vol.170, p.S1037-S1039

2022

Volltextzugriff (PDF)

319TiP NeoBREASTIM: A phase II study of atezolizumab plus RP1 oncolytic immunotherapy in the neoadjuvant setting of triple-negative breast cancer (TNBC)

Annals of oncology, 2024-09, Vol.35, p.S347-S348

2024

Volltextzugriff (PDF)

Multiepitopic HLA-A0201-Restricted Immune Response Against Hepatitis B Surface Antigen After DNA-Based Immunization

The Journal of immunology (1950), 2000-10, Vol.165 (8), p.4748-4755

2000

Volltextzugriff (PDF)

1 – 25 von 396

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(324)
Mit Volltextzugriff
(280)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies

A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma

Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer

Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program

Immunothérapie et cancer du sein

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer

Congrès Targeted Anticancer Therapies — TAT 2014

IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program

A Therapeutic Challenge: Chemo-refractory Non-metastatic Inflammatory Breast Cancers

P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator’s choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy

Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets

Concurrent radiation therapy and dual HER2 blockade in breast cancer: Assessment of toxicity

Association du double blocage de HER2 et radiothérapie dans la prise en charge du cancer du sein exprimant HER2

1810 Neoadjuvant chemotherapy modifies the immune status of tumor-draining lymph nodes of breast cancer patients: Implications for immunotherapy

Immune-checkpoint myocarditis phenotype when using systematic troponin surveillance in cancer patients

The safety of standardized management of suspected cardiovascular immune-related events in patients treated by immunecheckpoints inhibitors

PO-1229 Radiotherapy-based management of non-metastatic Inflammatory breast cancers: a retrospective study

319TiP NeoBREASTIM: A phase II study of atezolizumab plus RP1 oncolytic immunotherapy in the neoadjuvant setting of triple-negative breast cancer (TNBC)

Multiepitopic HLA-A0201-Restricted Immune Response Against Hepatitis B Surface Antigen After DNA-Based Immunization

Suchergebnisse filtern